Thalidomide (INN) and its salts
Thalidomide (INN) and its salts is listed in Annex II as a prohibited substance for cosmetic products placed on the EU market.
Chemical identity and properties
Thalidomide
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione is a dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group. It is a member of piperidones and a member of phthalimides. — ChEBI
- IUPAC name
- 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
- Molecular formula
- C13H10N2O4
- Molecular weight
- 258.23 g/mol
- Exact mass
- 258.06405680 Da
- XLogP3
- 0.3
- Topological polar surface area
- 83.6 Ų
- Hydrogen-bond donors
- 1
- Hydrogen-bond acceptors
- 4
- Covalent units
- 1
- Defined stereocentres
- 0
Also known as
16 more reported names
External database identifiers
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.
Record details
Chemical name
Thalidomide (INN) and its salts
Chemical / IUPAC name
1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- ; Phthalimide, N-(2,6-dioxo-3-piperidyl)-
Regulatory information
Key data
Related records for Thalidomide (INN) and its salts
Direct matches are limited for this record, so nearby entries from Annex II are shown as well.
Phosphorus and metalphosphides
Physostigma venenosum Balf.
Tetraethyl pyrophosphate (TEPP - ISO)
alpha-Piperidin-2-ylbenzyl acetate, laevorotatory threoform (levofacetoperane (INN)) and its salts
Triamterene (INN) and its salts
Pipradrol (INN) and its salts
Azacyclonol (INN) and its salts
What Annex II means for Thalidomide (INN) and its salts
Thalidomide (INN) and its salts is listed as a prohibited substance under Annex II of EU Cosmetics Regulation 1223/2009 and must not be intentionally added. Article 17 separately addresses unintended small quantities that are technically unavoidable under good manufacturing practice and compatible with the Article 3 safety requirement.
Formulators must screen their ingredients and raw materials to ensure none contain this substance. Suppliers should provide documentation confirming absence when requested.
The page also surfaces 12 related annex records with overlapping identifiers, annex logic or naming patterns.
Compliance checklist
- Verify this substance is absent from all raw materials and finished formulations.
- Request absence confirmation or CoA from raw material suppliers.
- Document the screening result in the Product Information File (PIF).
Frequently asked questions
Source note for Annex II record Thalidomide (INN) and its salts
This page summarizes one Annex II record for Thalidomide (INN) and its salts from public European Commission cosmetic materials and adds linked inventory or identifier matches when available.
Use this record page to review Annex II conditions for Thalidomide (INN) and its salts, but confirm any final regulatory decision against the current official annex wording and source files.
Tools & next steps
Check your formula
Paste a full INCI list to detect Thalidomide (INN) and its salts and other flagged EU annex records in one pass.
INCI CheckerCompare entries
Compare Thalidomide (INN) and its salts side by side with another annex record to review differences in restrictions, concentrations and annex placement.
CompareBrowse the annex
See all records in Annex II and compare regulatory conditions across substances in this annex.
Open Annex II